27th November 2014

ASX ANNOUNCEMENT

RESULTS OF ANNUAL GENERAL MEETING

Analytica Limited (ASX: ALT) advises that all resolutions were passed by a show of hands.

Proxy votes received were as follows:

Resolution	For	Open votes (Chairman nominated as proxy)	**Total Votes For the resolution**	Against
1. Remuneration report %	56,867,672 67.47%	7,509,852 8.91%	**64,377,524** **76.38%**	19,921,779 23.63%
2. Re-election of Mr Warren Brooks	208,895,034	8,068,956	**216,963,990**	6,964,501
3. Election of Mr Carl Stubbings	240,102,259	9,340,684	**249,442,943**	6,991,951
4. Ratification of April 2014 Placement	68,420,141	7,874,961	**76,295,102**	7,440,200
5. Ratification of October 2014 Placement	68,068,197	8,289,406	**76,357,603**	7,497,700
6. Special Resolution - Approval of Enhanced Placement Capacity %	226,725,838 88.25%	7,885,586 3.07%	**234,611,424** **91.32%**	22,308,946 8.68%

About Analytica Limited

Analytica's lead product is the PeriCoach™ System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach™ comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is correctly performing pelvic floor exercises and if these are improving her condition; otherwise physicians are guided on the need for surgery.

PeriCoach™ has been approved in Australia with product launches expected in 2014 in Australia, and Europe and the US in 2015. The US market for incontinence pads is $5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence. The product is not available for sale in the USA.

Analytica is also commercialising the AutoStart™ Infusion System. This is a burette with improved safety and cost reduction features. It is targeting a $3 billion pa global market, has FDA approval and potential near term cash flow with distribution agreements.